In the present study, we evaluated the capacity to predict AKI, mortality, as well as other short-/long-term outcomes of a combined biomarker that included three plasma proteins: fibroblast growth factor-23 (FGF23), Klotho and erythropoietin (EPO) [19,20,21]. The gene discussed is KL; the disease is acute kidney injury.